These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38462769)

  • 21. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Nevitt SJ; Jones AP; Howard J
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
    Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
    J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study.
    Allali S; Galactéros F; Oevermann L; Cannas G; Joseph L; Loko G; Elenga N; Benkerrou M; Etienne-Julan M; Castex MP; Brousse V; de Montalembert M
    Am J Hematol; 2024 Apr; 99(4):555-561. PubMed ID: 38247384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
    J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
    Kang HA; Barner JC
    J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
    [No Abstract]   [Full Text] [Related]  

  • 27. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

  • 28. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
    Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
    Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K; Smith-Whitley K
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea.
    Nevin J; Myers L; Osunkwo I; Kanter J
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e180-4. PubMed ID: 24072249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study.
    de Montalembert M; Voskaridou E; Oevermann L; Cannas G; Habibi A; Loko G; Joseph L; Colombatti R; Bartolucci P; Brousse V; Galactéros F;
    Am J Hematol; 2021 Oct; 96(10):1223-1231. PubMed ID: 34224583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
    Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
    J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
    Keikhaei B; Yousefi H; Bahadoram M
    Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal doses of hydroxyurea for sickle cell disease.
    Lima CS; Arruda VR; Costa FF; Saad ST
    Braz J Med Biol Res; 1997 Aug; 30(8):933-40. PubMed ID: 9361721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea for the treatment of sickle cell disease.
    Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
    Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
    Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
    Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
    Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
    BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
    Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
    JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.